Skip to main content
OpenTrials
Completed

NCT Number: NCT04407481

PErfusioN, OxyGen ConsUmptIon and ENergetics in ADPKD (PENGUIN)

Autosomal dominant polycystic kidney disease (ADPKD) is the most common monogenic cause of end-stage kidney disease (ESKD). The disorder is characterized by development and continued growth of multiple cysts requiring renal replacement therapy in 50% of patients by age 60 years. However, ADPKD is also a complex metabolic disorder defined by insulin resistance (IR) and mitochondrial dysfunction which may be causally related to cyst expansion, kidney function decline and contribute to reduced life expectancy. Renal hypoxia, stemming from a potential metabolic mismatch between increased renal energy expenditure and impaired substrate utilization, is proposed as a novel unifying early pathway in the development and expansion of renal cysts in ADPKD. By examining the interplay between renal O2 consumption and energy utilization in young adults with and without ADPKD, the investigators hope to identify novel therapeutic targets to impede development of cyst expansion in future trials.

The investigators propose to address the specific aims in a cross-sectional study with 20 adults with ADPKD (50% female, ages 18-40 years). Comparative data will be provided from healthy adults from an ongoing study with similar study design and methods (CROCODILE Study: Control of Renal Oxygen Consumption, Mitochondrial Dysfunction, and Insulin Resistance). For this protocol, participants will complete a one day study visit at Children's Hospital Colorado. Patients will undergo a dual energy x-ray absorptiometry (DXA) to assess body composition, and a 11C-acetate positron emission tomography (PET/CT) scan to quantify renal O2 consumption. After the PET/CT, participants will undergo a hyperinsulinemic-euglycemic clamp while fasting to quantify insulin sensitivity. Glomerular Filtration Rate (GFR) and Effective Renal Plasma Flow (ERPF) will be measured by iohexol and PAH clearances during the hyperinsulinemic-euglycemic clamp.

Completed

Looking for future studies?

Notify Me

Key information

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients with Autosomal dominant polycystic kidney disease
  • Age 18-40 years
  • BMI >= 18.5 and <30 kg/m2
  • Weight <350 lbs

Exclusion criteria

  • Diabetes mellitus, based on previous diagnosis
  • Albuminuria (≥30mg/g) or estimated glomerular filtration rate (eGFR) <75ml/min/1.73m2
  • Pregnancy or nursing
  • Anemia
  • Allergy to shellfish or iodine
  • Vaptan therapy (e.g. tolvaptan)
  • Uncontrolled hypertension (average ≥140/90 mmHg)

Treatment and study plan

Aminohippurate Sodium Inj 20%

Drug

Diagnostic aid/agent used to measure effective renal plasma flow (ERPF)

Other names: •- Sodium 4-amino hippurate (PAH) inj 20% 2g/10 milliliter (mL) • Para-aminohippurate • Aminohippuric acid

Iohexol Inj 300 milligrams per milliliter (MG/ML)

Drug

Diagnostic aid/agent used to measure glomerular filtration rate (GFR)

Other names: omnipaque 300

PET/CT Scan

Radiation

Imaging used to visualize the kidneys and quantify renal metabolic activity

Primary outcomes

  1. Renal oxygen consumption

    Time frame: 30 minutes

    11-C Acetate PET/CT

  2. Insulin Sensitivity

    Time frame: 4.5 hours

    Hyperinsulinemic-Euglycemic Clamp

Secondary outcomes

  1. Mitochondrial Function

    Time frame: 5 minutes

    Blood draw for mitochondrial DNA copy number

  2. Mitochondrial Function

    Time frame: 5 minutes

    Blood draw for untargeted metabolite assessment of the tricyclic acid (TCA) cycle

  3. Mitochondrial Function

    Time frame: 5 minutes

    Blood draw for targeted assessment and quantification of glucose oxidation using an established metabolite panel

  4. Mitochondrial Function

    Time frame: 5 minutes

    Blood draw for untargeted metabolite assessment of Free Fatty Acid (FFA) oxidation

  5. Glomerular Filtration Rate (GFR)

    Time frame: 3 hours

    Iohexol Clearance Study

  6. Effective Renal Plasma Flow (ERPF)

    Time frame: 2.5 hours

    PAH Clearance Study

  7. Renin-Angiotensin-Aldosterone-System Activity

    Time frame: 5 minutes

    Blood draw for Plasma Renin levels

  8. Renin-Angiotensin-Aldosterone-System Activity

    Time frame: 5 minutes

    Blood draw for Angiotensin II levels

  9. Renin-Angiotensin-Aldosterone-System Activity

    Time frame: 5 minutes

    Blood draw for Copeptin levels

  10. Kidney Injury Biomarkers

    Time frame: 5 minutes

    Chitinase-3-like protein 1 (YKL-40) levels

  11. Kidney Injury Biomarkers

    Time frame: 5 minutes

    Blood draw for Neutrophil gelatinase-associated lipocalin (NGAL) levels

  12. Kidney Injury Biomarkers

    Time frame: 5 minutes

    Blood draw for Kidney Injury Molecule 1 (KIM-1) levels

  13. Kidney Injury Biomarkers

    Time frame: 5 minutes

    Blood draw for Interleukin-18 (IL-18) levels

  14. Kidney Injury Biomarkers

    Time frame: 5 minutes

    Blood draw for Tumor Necrosis Factor Receptor 1/2 (TNF-R 1/2) levels

  15. Kidney Injury Biomarkers

    Time frame: 5 minutes

    Blood draw for monocyte chemoattractant protein-1 (MCP-1) levels

Sponsors and collaborators

Lead sponsor

University of Colorado, Denver

Other

Registry information

Official study title

PENGUIN: PErfusioN, OxyGen ConsUmptIon and ENergetics in ADPKD

Acronym: PENGUIN

Important dates

Study start
2020
Primary completion
2022
Study completion
2022
First posted
May 29, 2020
Registry last updated
Feb 3, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.